Ranbaxy’s arm gets approval to manufacture and market RAN-Rosuvastatin tablets

31 Mar 2012 Evaluate

Ranbaxy Laboratories’ (RLL) - wholly owned subsidiary - Ranbaxy Pharmaceuticals Canada Inc. (RPCI), has received approval from Health Canada to manufacture and market RAN-Rosuvastatin tablets to the Canadian healthcare system. 

Rosuvastatin is a HMG-COA Reductase Inhibitor, a cholesterol-lowering medication. The brand sales of Crestor in Canada were $742.2 million ($CAD-IMS-CDH: January, 2012). The finished dosage form was developed, and will be manufactured within RLL's Health Canada approved facilities located in India. The company anticipates making Rosuvastatin tablets available to all classes of trade after April 2 when sufficient supplies will be available to meet market demand.

RPCI is engaged in the sale and distribution of generic prescription products in the Canadian healthcare system.

Ranbaxy Laboratories, India's largest pharmaceutical company, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies.

Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×